KI
Kilitch Drugs (India) Limited
KILITCH.NS · NSE
₹245.00 -4.39% (-₹11.25)
1M +36.39%
Market Cap ₹8.94B
P/E Ratio 29.73x
Div. Yield -
ROE 11.90%
Bulios Fair Price
₹159.81
34.8% downside
Current Price
₹245
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KILITCH.NS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
34 /100
Fair P/E 29.73x
EV/EBITDA 22.24x
P/S 3.77x
Growth
100 /100
Growing EPS growth 39.46%
Rev. growth 19.04%
Book val. growth 22.64%
Profitability
48 /100
Moderate Gross margin 39.01%
Net margin 12.67%
Op. margin 13.66%
Quality
46 /100
Average ROIC 6.61%
ROE 11.90%
ROA 6.57%
Debt
83 /100
Low Debt/Equity 0.32x
Current ratio 1.83x
Int. coverage 8.06x
Stability
70 /100
Stable Beta 0.36x
Rev. volatility 9.55%
EPS volatility 36.02%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KILITCH.NS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mukund Prataprai Mehta
Employees
236
Headquarters
Mumbai